The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Co-development of precision RNA therapeutics for inherited hearing loss treatment SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company ...

"We are thrilled to collaborate with Lilly, a global leader in pharmaceutical innovation," said Dr. Seong-Wook Lee, CEO of Rznomics. "This partnership validates our trans-splicing ribozyme platform ...

"We are thrilled to collaborate with Lilly, a global leader in pharmaceutical innovation," said Dr. Seong-Wook Lee, CEO of Rznomics. "This partnership validates our trans-splicing ribozyme ...